APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin 17A

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Interleukin 17A Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchInterleukin 17A Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin 17A Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Interleukin 17A Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin 17A Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin 17A Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Interleukin 17A market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Interleukin 17A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin 17A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin 17A is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Interleukin 17A market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Interleukin 17A market include Abeome Corporation, Affibody AB, Cell Medica Limited, Orega Biotech SAS, AbbVie Inc, Eli Lilly and Company, Merck KGaA, Novartis AG and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin 17A market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin 17A and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin 17A sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin 17A market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin 17A Segment by Company

Abeome Corporation

Affibody AB

Cell Medica Limited

Orega Biotech SAS

AbbVie Inc

Eli Lilly and Company

Merck KGaA

Novartis AG

Johnson & Johnson

Interleukin 17A Segment by Type

DLX-2882

CNTO-6785

ABY-035

Others

Interleukin 17A Segment by Application

Kidney Cancer

Chronic Pain

Liver Cancer

Others

Interleukin 17A Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Interleukin 17A status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Interleukin 17A market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Interleukin 17A significant trends, drivers, influence factors in global and regions.

6. To analyze Interleukin 17A competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 17A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin 17A and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 17A.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin 17A market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Interleukin 17A industry.

Chapter 3: Detailed analysis of Interleukin 17A manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Interleukin 17A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Interleukin 17A in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Interleukin 17A Industry Trends Table 2. Interleukin 17A Industry Drivers Table 3. Interleukin 17A Industry Opportunities and Challenges Table 4. Interleukin 17A Industry Restraints Table 5. Global Interleukin 17A Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Interleukin 17A Revenue Share by Company (2021-2026) Table 7. Global Interleukin 17A Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Interleukin 17A Sales Volume Share by Company (2021-2026) Table 9. Global Interleukin 17A Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Interleukin 17A Company Ranking, (2024-2026) & (USD Million) Table 11. Global Interleukin 17A Key Company Manufacturing Base & Headquarters Table 12. Global Interleukin 17A Company, Product Type & Application Table 13. Global Interleukin 17A Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin 17A by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of DLX-2882 Table 18. Significant Companies of CNTO-6785 Table 19. Significant Companies of ABY-035 Table 20. Significant Companies of Others Table 21. Global Interleukin 17A Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Interleukin 17A Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Interleukin 17A Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Interleukin 17A Sales Volume Share by Type (2021-2026) Table 25. Global Interleukin 17A Sales Volume Share by Type (2027-2032) Table 26. Global Interleukin 17A Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Interleukin 17A Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Interleukin 17A Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Interleukin 17A Sales Value Share by Type (2021-2026) Table 30. Global Interleukin 17A Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Kidney Cancer Table 32. Significant Companies of Chronic Pain Table 33. Significant Companies of Liver Cancer Table 34. Significant Companies of Others Table 35. Global Interleukin 17A Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Interleukin 17A Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Interleukin 17A Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Interleukin 17A Sales Volume Share by Application (2021-2026) Table 39. Global Interleukin 17A Sales Volume Share by Application (2027-2032) Table 40. Global Interleukin 17A Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Interleukin 17A Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Interleukin 17A Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Interleukin 17A Sales Value Share by Application (2021-2026) Table 44. Global Interleukin 17A Sales Value Share by Application (2027-2032) Table 45. Global Interleukin 17A Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Interleukin 17A Sales by Region (2021-2026) & (W Units) Table 47. Global Interleukin 17A Sales Market Share by Region (2021-2026) Table 48. Global Interleukin 17A Sales by Region (2027-2032) & (W Units) Table 49. Global Interleukin 17A Sales Market Share by Region (2027-2032) Table 50. Global Interleukin 17A Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Interleukin 17A Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Interleukin 17A Sales Value Share by Region (2021-2026) Table 53. Global Interleukin 17A Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Interleukin 17A Sales Value Share by Region (2027-2032) Table 55. Global Interleukin 17A Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Interleukin 17A Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Interleukin 17A Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Interleukin 17A Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Interleukin 17A Sales by Country (2021-2026) & (W Units) Table 60. Global Interleukin 17A Sales Market Share by Country (2021-2026) Table 61. Global Interleukin 17A Sales by Country (2027-2032) & (W Units) Table 62. Global Interleukin 17A Sales Market Share by Country (2027-2032) Table 63. Global Interleukin 17A Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Interleukin 17A Sales Value Market Share by Country (2021-2026) Table 65. Global Interleukin 17A Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Interleukin 17A Sales Value Market Share by Country (2027-2032) Table 67. Abeome Corporation Company Information Table 68. Abeome Corporation Business Overview Table 69. Abeome Corporation Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Abeome Corporation Interleukin 17A Product Portfolio Table 71. Abeome Corporation Recent Development Table 72. Affibody AB Company Information Table 73. Affibody AB Business Overview Table 74. Affibody AB Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Affibody AB Interleukin 17A Product Portfolio Table 76. Affibody AB Recent Development Table 77. Cell Medica Limited Company Information Table 78. Cell Medica Limited Business Overview Table 79. Cell Medica Limited Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Cell Medica Limited Interleukin 17A Product Portfolio Table 81. Cell Medica Limited Recent Development Table 82. Orega Biotech SAS Company Information Table 83. Orega Biotech SAS Business Overview Table 84. Orega Biotech SAS Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Orega Biotech SAS Interleukin 17A Product Portfolio Table 86. Orega Biotech SAS Recent Development Table 87. AbbVie Inc Company Information Table 88. AbbVie Inc Business Overview Table 89. AbbVie Inc Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AbbVie Inc Interleukin 17A Product Portfolio Table 91. AbbVie Inc Recent Development Table 92. Eli Lilly and Company Company Information Table 93. Eli Lilly and Company Business Overview Table 94. Eli Lilly and Company Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eli Lilly and Company Interleukin 17A Product Portfolio Table 96. Eli Lilly and Company Recent Development Table 97. Merck KGaA Company Information Table 98. Merck KGaA Business Overview Table 99. Merck KGaA Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Merck KGaA Interleukin 17A Product Portfolio Table 101. Merck KGaA Recent Development Table 102. Novartis AG Company Information Table 103. Novartis AG Business Overview Table 104. Novartis AG Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis AG Interleukin 17A Product Portfolio Table 106. Novartis AG Recent Development Table 107. Johnson & Johnson Company Information Table 108. Johnson & Johnson Business Overview Table 109. Johnson & Johnson Interleukin 17A Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Johnson & Johnson Interleukin 17A Product Portfolio Table 111. Johnson & Johnson Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Interleukin 17A Distributors List Table 115. Interleukin 17A Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Interleukin 17A Product Image Figure 2. Global Interleukin 17A Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 4. Global Interleukin 17A Sales (2021-2032) & (W Units) Figure 5. Global Interleukin 17A Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Interleukin 17A Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. DLX-2882 Image Figure 10. CNTO-6785 Image Figure 11. ABY-035 Image Figure 12. Others Image Figure 13. Global Interleukin 17A Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Interleukin 17A Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Interleukin 17A Sales Volume Share by Type (2021-2032) Figure 16. Global Interleukin 17A Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Interleukin 17A Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Interleukin 17A Sales Value Share by Type (2021-2032) Figure 19. Kidney Cancer Image Figure 20. Chronic Pain Image Figure 21. Liver Cancer Image Figure 22. Others Image Figure 23. Global Interleukin 17A Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Interleukin 17A Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Interleukin 17A Sales Volume Share by Application (2021-2032) Figure 26. Global Interleukin 17A Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Interleukin 17A Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Interleukin 17A Sales Value Share by Application (2021-2032) Figure 29. Global Interleukin 17A Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Interleukin 17A Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Interleukin 17A Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Interleukin 17A Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 34. North America Interleukin 17A Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Interleukin 17A Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Interleukin 17A Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 40. South America Interleukin 17A Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Interleukin 17A Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Interleukin 17A Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Interleukin 17A Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Interleukin 17A Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Interleukin 17A Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Interleukin 17A Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Interleukin 17A Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • DLX-2882
  • CNTO-6785
  • ABY-035
  • Others
Applications
  • Kidney Cancer
  • Chronic Pain
  • Liver Cancer
  • Others
Companies covered
  • Abeome Corporation
  • Affibody AB
  • Cell Medica Limited
  • Orega Biotech SAS
  • AbbVie Inc
  • Eli Lilly and Company
  • Merck KGaA
  • Novartis AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Interleukin 17A Sales Value (2021-2032)
  4. 1.2.2 Global Interleukin 17A Sales Volume (2021-2032)
  5. 1.2.3 Global Interleukin 17A Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Interleukin 17A Market Dynamics
  1. 2.1 Interleukin 17A Industry Trends
  2. 2.2 Interleukin 17A Industry Drivers
  3. 2.3 Interleukin 17A Industry Opportunities and Challenges
  4. 2.4 Interleukin 17A Industry Restraints
3 Interleukin 17A Market by Company
  1. 3.1 Global Interleukin 17A Company Revenue Ranking in 2025
  2. 3.2 Global Interleukin 17A Revenue by Company (2021-2026)
  3. 3.3 Global Interleukin 17A Sales Volume by Company (2021-2026)
  4. 3.4 Global Interleukin 17A Average Price by Company (2021-2026)
  5. 3.5 Global Interleukin 17A Company Ranking (2024-2026)
  6. 3.6 Global Interleukin 17A Company Manufacturing Base and Headquarters
  7. 3.7 Global Interleukin 17A Company Product Type and Application
  8. 3.8 Global Interleukin 17A Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Interleukin 17A Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Interleukin 17A Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Interleukin 17A Market by Type
  1. 4.1 Interleukin 17A Type Introduction
  2. 4.1.1 DLX-2882
  3. 4.1.2 CNTO-6785
  4. 4.1.3 ABY-035
  5. 4.1.4 Others
  6. 4.2 Global Interleukin 17A Sales Volume by Type
  7. 4.2.1 Global Interleukin 17A Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Interleukin 17A Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Interleukin 17A Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Interleukin 17A Sales Value by Type
  11. 4.3.1 Global Interleukin 17A Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Interleukin 17A Sales Value by Type (2021-2032)
  13. 4.3.3 Global Interleukin 17A Sales Value Share by Type (2021-2032)
5 Interleukin 17A Market by Application
  1. 5.1 Interleukin 17A Application Introduction
  2. 5.1.1 Kidney Cancer
  3. 5.1.2 Chronic Pain
  4. 5.1.3 Liver Cancer
  5. 5.1.4 Others
  6. 5.2 Global Interleukin 17A Sales Volume by Application
  7. 5.2.1 Global Interleukin 17A Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Interleukin 17A Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Interleukin 17A Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Interleukin 17A Sales Value by Application
  11. 5.3.1 Global Interleukin 17A Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Interleukin 17A Sales Value by Application (2021-2032)
  13. 5.3.3 Global Interleukin 17A Sales Value Share by Application (2021-2032)
6 Interleukin 17A Regional Sales and Value Analysis
  1. 6.1 Global Interleukin 17A Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin 17A Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin 17A Sales by Region: 2021-2026
  4. 6.2.2 Global Interleukin 17A Sales by Region (2027-2032)
  5. 6.3 Global Interleukin 17A Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Interleukin 17A Sales Value by Region (2021-2032)
  7. 6.4.1 Global Interleukin 17A Sales Value by Region: 2021-2026
  8. 6.4.2 Global Interleukin 17A Sales Value by Region (2027-2032)
  9. 6.5 Global Interleukin 17A Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Interleukin 17A Sales Value (2021-2032)
  12. 6.6.2 North America Interleukin 17A Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Interleukin 17A Sales Value (2021-2032)
  15. 6.7.2 Europe Interleukin 17A Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Interleukin 17A Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Interleukin 17A Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Interleukin 17A Sales Value (2021-2032)
  21. 6.9.2 South America Interleukin 17A Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Interleukin 17A Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Interleukin 17A Sales Value Share by Country, 2025 VS 2032
7 Interleukin 17A Country-level Sales and Value Analysis
  1. 7.1 Global Interleukin 17A Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Interleukin 17A Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Interleukin 17A Sales by Country (2021-2032)
  4. 7.3.1 Global Interleukin 17A Sales by Country (2021-2026)
  5. 7.3.2 Global Interleukin 17A Sales by Country (2027-2032)
  6. 7.4 Global Interleukin 17A Sales Value by Country (2021-2032)
  7. 7.4.1 Global Interleukin 17A Sales Value by Country (2021-2026)
  8. 7.4.2 Global Interleukin 17A Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Interleukin 17A Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Interleukin 17A Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Interleukin 17A Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Interleukin 17A Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Interleukin 17A Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Interleukin 17A Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Interleukin 17A Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Interleukin 17A Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Interleukin 17A Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Interleukin 17A Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Interleukin 17A Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Interleukin 17A Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Interleukin 17A Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Interleukin 17A Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Interleukin 17A Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Interleukin 17A Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Interleukin 17A Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Interleukin 17A Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Interleukin 17A Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Interleukin 17A Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Interleukin 17A Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Interleukin 17A Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Interleukin 17A Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Interleukin 17A Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Interleukin 17A Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Interleukin 17A Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Interleukin 17A Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Interleukin 17A Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Interleukin 17A Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Interleukin 17A Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Interleukin 17A Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abeome Corporation
  2. 8.1.1 Abeome Corporation Company Information
  3. 8.1.2 Abeome Corporation Business Overview
  4. 8.1.3 Abeome Corporation Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abeome Corporation Interleukin 17A Product Portfolio
  6. 8.1.5 Abeome Corporation Recent Developments
  7. 8.2 Affibody AB
  8. 8.2.1 Affibody AB Company Information
  9. 8.2.2 Affibody AB Business Overview
  10. 8.2.3 Affibody AB Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Affibody AB Interleukin 17A Product Portfolio
  12. 8.2.5 Affibody AB Recent Developments
  13. 8.3 Cell Medica Limited
  14. 8.3.1 Cell Medica Limited Company Information
  15. 8.3.2 Cell Medica Limited Business Overview
  16. 8.3.3 Cell Medica Limited Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cell Medica Limited Interleukin 17A Product Portfolio
  18. 8.3.5 Cell Medica Limited Recent Developments
  19. 8.4 Orega Biotech SAS
  20. 8.4.1 Orega Biotech SAS Company Information
  21. 8.4.2 Orega Biotech SAS Business Overview
  22. 8.4.3 Orega Biotech SAS Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Orega Biotech SAS Interleukin 17A Product Portfolio
  24. 8.4.5 Orega Biotech SAS Recent Developments
  25. 8.5 AbbVie Inc
  26. 8.5.1 AbbVie Inc Company Information
  27. 8.5.2 AbbVie Inc Business Overview
  28. 8.5.3 AbbVie Inc Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Inc Interleukin 17A Product Portfolio
  30. 8.5.5 AbbVie Inc Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Interleukin 17A Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Merck KGaA
  38. 8.7.1 Merck KGaA Company Information
  39. 8.7.2 Merck KGaA Business Overview
  40. 8.7.3 Merck KGaA Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck KGaA Interleukin 17A Product Portfolio
  42. 8.7.5 Merck KGaA Recent Developments
  43. 8.8 Novartis AG
  44. 8.8.1 Novartis AG Company Information
  45. 8.8.2 Novartis AG Business Overview
  46. 8.8.3 Novartis AG Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis AG Interleukin 17A Product Portfolio
  48. 8.8.5 Novartis AG Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson Interleukin 17A Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson Interleukin 17A Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin 17A Value Chain Analysis
  2. 9.1.1 Interleukin 17A Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin 17A Sales Mode & Process
  6. 9.2 Interleukin 17A Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin 17A Distributors
  9. 9.2.3 Interleukin 17A Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst